TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29394918

Group type: EXPERIMENTAL
Intervention: Once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for up to 24 months; follow-up includes testing for HIV at 1 month, HIV and other sexually transmissible infections three-monthly, HCV annually, and renal function monitoring six-monthly.
Number of subjects: 3700
Study: 29394922

Group type: EXPERIMENTAL
Intervention: Higher grip strength (highest tertile)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Vitamin D sufficiency
Number of subjects: 350
Study: 29395172

Group type: EXPERIMENTAL
Intervention: Desmopressin (acute and long term use)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fluid restriction and salt tablets for SIADH
Number of subjects: 160
Study: 29395858

Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal Intervention for Suicide Prevention (CRISP)
Number of subjects: 0
Study: 29395863

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 40
Study: 29395867

Group type: EXPERIMENTAL
Intervention: Chemotherapy (platinum-based)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Chemotherapy (taxane)
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Gastrointestinal cancers
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Thyroid cancers
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Abdominal or cervical surgery
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Overall treatment during pregnancy
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1170
Study: 29396091

Group type: EXPERIMENTAL
Intervention: Ibrutinib, lenalidomide, and rituximab (induction phase: 12 cycles of 28 days; maintenance phase: ibrutinib and rituximab only, cycle duration 56 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ibrutinib, lenalidomide, and rituximab (induction phase)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ibrutinib, lenalidomide, and rituximab
Number of subjects: 50
Study: 29396094

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide [750 mg/m2], doxorubicin, vincristine, and prednisone) followed by radioimmunotherapy and maintenance rituximab for 4 years
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: R-CHOP and radioimmunotherapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall therapeutic strategy (R-CHOP, radioimmunotherapy, and maintenance rituximab)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 84
Study: 29396259

Group type: EXPERIMENTAL
Intervention: Parental supply of alcohol
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Supply from other sources
Number of subjects: 1927

Group type: COMPARATOR
Intervention: No supply from any source
Number of subjects: 1927
Study: 29396389

Group type: EXPERIMENTAL
Intervention: Mobile intervention group (various levels of physician access to patient data)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 163
Study: 29396857

Group type: EXPERIMENTAL
Intervention: FLAI-GO induction regimen (fludarabine 30 mg/sqm, cytarabine 2 g/sqm, idarubicin 10 mg/sqm, Gemtuzumab-Ozogamicin 3 mg/sqm)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: FLAI-GO induction regimen
Number of subjects: 130
Study: 29397019

Group type: EXPERIMENTAL
Intervention: Blood collection tubes (BCT) (Streck)
Number of subjects: 50

Group type: COMPARATOR
Intervention: K3EDTA tubes
Number of subjects: 50
Study: 29397118

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 5749

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 5749
Study: 29397116

Group type: EXPERIMENTAL
Intervention: IVC ultrasound-guided volume management
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no IVCUS assessment)
Number of subjects: 160
Study: 29397119

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 256
Study: 29397139

Group type: EXPERIMENTAL
Intervention: Presurgical antiplatelet therapy (APT) prescribed in 95% of procedures; preoperatively discontinued in 15%.
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: No preoperative APT
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Major bleeding events (MBE)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Recent myocardial infarction
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 432
Study: 29397225

Group type: EXPERIMENTAL
Intervention: Booster vaccination with polygeline-free inactivated TBE vaccine (TBEvac)
Number of subjects: 191
Study: 29397305

Group type: EXPERIMENTAL
Intervention: Mutation carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 0
Study: 29397334

Group type: EXPERIMENTAL
Intervention: 100-150 keV noise-optimized virtual monoenergetic images
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 40 keV noise-optimized virtual monoenergetic images
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 40-70 keV noise-optimized virtual monoenergetic images and 70 keV virtual monoenergetic images
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 70 keV noise-optimized virtual monoenergetic images
Number of subjects: 51
Study: 29398518

Group type: EXPERIMENTAL
Intervention: Hyperemesis gravidarum (HG)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no Hyperemesis gravidarum)
Number of subjects: 79
Study: 29398546

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 4111

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 4111

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 4111

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4111
Study: 29398594

Group type: EXPERIMENTAL
Intervention: Degarelix for 8 weeks
Number of subjects: 50
Study: 29398640

Group type: EXPERIMENTAL
Intervention: Mepolizumab intervention
Number of subjects: 572
Study: 29398998

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29399054

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (CT) 3.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29399258

Group type: EXPERIMENTAL
Intervention: Ingenol Disoxate (LEO 43204), treatment duration not specified
Number of subjects: 0
Study: 29399263

Group type: EXPERIMENTAL
Intervention: Ingenol Disoxate (LEO 43204)
Number of subjects: 0
Study: 29399976

Group type: EXPERIMENTAL
Intervention: 5-week very-low-calorie diet (500 kcal/d) followed by a 4-week weight-stable diet (WS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Uncontrolled 9-month follow-up
Number of subjects: 31
Study: 29400693

Group type: EXPERIMENTAL
Intervention: Mucus plugs in subjects with asthma
Number of subjects: 146

Group type: COMPARATOR
Intervention: Mucus plugs in controls
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: High mucus score (plugs in ≥ 4 segments) in subjects with asthma
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Eosinophil peroxidase (EPO) activity
Number of subjects: 146
Study: 29401002

Group type: EXPERIMENTAL
Intervention: Alpelisib 400 mg once daily
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Alpelisib 150 mg twice daily
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Alpelisib (various doses)
Number of subjects: 134
Study: 29401079

Group type: EXPERIMENTAL
Intervention: Propofol pharmacokinetic (PK) pharmacodynamic (PD) model
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Current model
Number of subjects: 47

Group type: COMPARATOR
Intervention: PK model developed by Eleveld et al
Number of subjects: 47
Study: 29401080

Group type: COMPARATOR
Intervention: Continuous oxytocin pretreatment (10(-5) M for 2 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intermittent oxytocin pretreatment (alternating 10(-5) M and physiological salt solution every 15 minutes for 2 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 18
Study: 29402064

Group type: EXPERIMENTAL
Intervention: Standard-dose intravenous alteplase (0.9 mg/kg)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase (0.6 mg/kg)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Both doses of intravenous alteplase
Number of subjects: 351
Study: 29402187

Group type: EXPERIMENTAL
Intervention: Enhanced inpatient rounds, appointment reminders, and patient education
Number of subjects: 240

Group type: COMPARATOR
Intervention: Preintervention period (control)
Number of subjects: 240

Group type: COMPARATOR
Intervention: New diagnosis of HIV infection (control)
Number of subjects: 240
Study: 29402243

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs), specifically gefitinib
Number of subjects: 334

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 334
Study: 29402246

Group type: EXPERIMENTAL
Intervention: Personal social networks (size=5.6, SD=2.6), kin-centered (proportion kin=0.71, SD=0.28), and dense networks.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Affiliation with religious and spiritual organizations.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Networks with higher density and more kin.
Number of subjects: 700
Study: 29402313

Group type: EXPERIMENTAL
Intervention: Care supported by a dedicated 'community-acquired pneumonia service' (multidisciplinary team deploying algorithm-based implementation of a bundle of four evidence-based interventions)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Care supported by a dedicated 'community-acquired pneumonia service'
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual medical, nursing and allied health care delivered according to existing organisational practice
Number of subjects: 8
Study: 29402319

Group type: EXPERIMENTAL
Intervention: Education and treatment programme combined with flash glucose monitoring device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 29402444

Group type: EXPERIMENTAL
Intervention: Nasal alar sensor
Number of subjects: 43

Group type: COMPARATOR
Intervention: Forehead sensor
Number of subjects: 43
Study: 29402632

Group type: EXPERIMENTAL
Intervention: Overnight video-EEG (average 9.65h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Routine EEG (approximately 25min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Follow-up EEG
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall EEG findings
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clinical observation
Number of subjects: 16
Study: 29402761

Group type: EXPERIMENTAL
Intervention: Fitbit One worn daily throughout the 12-week intervention
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Self-reported frequency of looking at activity data on the Fitbit tracker and app or website at week 12
Number of subjects: 42
Study: 29403411

Group type: EXPERIMENTAL
Intervention: Tools of the Mind preschool curriculum
Number of subjects: 260

Group type: COMPARATOR
Intervention: YMCA PTL (Playing to Learn)
Number of subjects: 260
Study: 29403482

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 2
Study: 29403531

Group type: EXPERIMENTAL
Intervention: Granulocyte-monocyte apheresis
Number of subjects: 33
Study: 29403650

Group type: EXPERIMENTAL
Intervention: RESHAPE intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training as usual (TAU)
Number of subjects: 0
Study: 29404331

Group type: EXPERIMENTAL
Intervention: 17.5 g/day cooked navy bean powder
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 15 g/day heat-stabilized rice bran
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 9 g/day navy beans and 8 g/day rice bran
Number of subjects: 38

Group type: COMPARATOR
Intervention: no navy bean or rice bran (control)
Number of subjects: 38
Study: 29404492

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) with concomitant proton pump inhibitor (PPI) use
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) without concomitant proton pump inhibitor (PPI) use
Number of subjects: 1322
Study: 29404572

Group type: EXPERIMENTAL
Intervention: Rideshare-based transportation services (complimentary ride-sharing)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Usual care (automated appointment phone call reminders)
Number of subjects: 786
Study: 29404713

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles (108 weeks)
Number of subjects: 716
Study: 29404723

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIV)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Mechanical cough assistance
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: NIV and mechanical cough assistance
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Reintubation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Chronic respiratory disease
Number of subjects: 130

Group type: COMPARATOR
Intervention: Endotracheal MV duration
Number of subjects: 130

Group type: COMPARATOR
Intervention: Medical Research Council (MRC) score
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Forced vital capacity (FVC)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Peak cough expiratory flow (PCEF)
Number of subjects: 130

Group type: COMPARATOR
Intervention: ROC curves for pre-extubation PCEF and FVC
Number of subjects: 130
Study: 29405350

Group type: EXPERIMENTAL
Intervention: Neurogenic OH (378 patients)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Nonneurogenic OH (24 patients)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: ΔHR/ΔSBP ratio
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Neurogenic OH (multiple system atrophy subgroup)
Number of subjects: 402
Study: 29405538

Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcome (ePRO) collection system
Number of subjects: 0
Study: 29405626

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg once daily for 6 weeks, followed by random assignment to either placebo or atrasentan 0.75 mg/day for responders (≥30% UACR decrease)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/day for non-responders (<30% UACR reduction)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Placebo for responders (≥30% UACR decrease)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Placebo for non-responders (<30% UACR reduction)
Number of subjects: 3500
Study: 29406178

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hscTnT) plasma concentrations measured at three time points: before operation, 2-6 h, and 18-30 h after surgery
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Postoperative hscTnT elevation >99th % upper reference limit (URL)
Number of subjects: 95
Study: 29406378

Group type: EXPERIMENTAL
Intervention: Pediatric residents as first laryngoscopists in PICUs with a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: Pediatric residents as first laryngoscopists in PICUs without a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: Overall resident participation trend
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: ICUs with a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203

Group type: EXPERIMENTAL
Intervention: ICUs without a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203

Group type: COMPARATOR
Intervention: Accreditation Council for Graduate Medical Education guideline change
Number of subjects: 9203
Study: 29406443

Group type: EXPERIMENTAL
Intervention: EDC organs
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard organs
Number of subjects: 79
Study: 29406772

Group type: EXPERIMENTAL
Intervention: Vilanterol alone
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol combination
Number of subjects: 16485

Group type: COMPARATOR
Intervention: Inhaled treatments (including vilanterol and fluticasone furoate/vilanterol)
Number of subjects: 16485
Study: 29406851

Group type: EXPERIMENTAL
Intervention: Dobutamine Stress Echocardiography (DSE) with peak stress mean gradient (MG) ≥40 mm Hg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Composite of peak stress MG ≥40 mm Hg and peak stress aortic valve area (AVA) ≤1 cm
Number of subjects: 186
Study: 29406857

Group type: EXPERIMENTAL
Intervention: Fluorine-18-NaF PET-CT
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control subjects (aortic diameter <30 mm)
Number of subjects: 92
Study: 29407077

Group type: EXPERIMENTAL
Intervention: BleeMACS risk score
Number of subjects: 15401
Study: 29407124

Group type: EXPERIMENTAL
Intervention: Systematic detection of asymptomatic MSAD combined with aggressive secondary prevention (n=263)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Conventional strategy based on treatment of coronary artery disease only with standard of care (n=258)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Systematic detection of asymptomatic MSAD combined with aggressive secondary prevention
Number of subjects: 521

Group type: COMPARATOR
Intervention: Conventional strategy based on treatment of coronary artery disease only with standard of care
Number of subjects: 521
Study: 29407285

Group type: EXPERIMENTAL
Intervention: Assessment during mania
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Assessment during euthymia
Number of subjects: 19
Study: 29407681

Group type: EXPERIMENTAL
Intervention: Drinking to cope
Number of subjects: 341
Study: 29408205

Group type: EXPERIMENTAL
Intervention: Mutation-positive families
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Mutation-negative families
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Both mutation-positive and mutation-negative families
Number of subjects: 1226

Group type: COMPARATOR
Intervention: General population
Number of subjects: 1226
Study: 29408538

Group type: EXPERIMENTAL
Intervention: Fastest tertile of quadriceps rate of force development (RFD)
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: Fastest tertile of quadriceps rate of force development (RFD) in women
Number of subjects: 2630

Group type: COMPARATOR
Intervention: Slowest tertile of quadriceps rate of force development (RFD)
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: Fastest tertile of quadriceps rate of force development (RFD) in men
Number of subjects: 2630
Study: 29408585

Group type: EXPERIMENTAL
Intervention: Upper Esophageal Sphincter Assist Device
Number of subjects: 0
Study: 29408590

Group type: EXPERIMENTAL
Intervention: Large Portion Size (PS) High Energy Density (ED)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Small Portion Size (PS) High Energy Density (ED)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Large Portion Size (PS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Small Portion Size (PS)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Responses in food salience regions
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Activation in control regions
Number of subjects: 47
Study: 29408715

Group type: EXPERIMENTAL
Intervention: Peanut extract stimulation for 6 to 18 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peanut allergy (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control (HC) subjects
Number of subjects: 0
Study: 29408981

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals on a low-sodium controlled diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with BMI ≥25 kg/m2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-HIV-infected individuals with BMI <25 kg/m2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison across four groups stratified by HIV serostatus and BMI
Number of subjects: 30
Study: 29408986

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Nivolumab in patients with liver metastases
Number of subjects: 854

Group type: COMPARATOR
Intervention: Docetaxel in patients with liver metastases
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Nivolumab (overall population)
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Nivolumab (liver metastases)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Docetaxel (overall population)
Number of subjects: 854
Study: 29408994

Group type: EXPERIMENTAL
Intervention: C-peptide positive (C-pos) patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: C-peptide negative (C-neg) patients
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: C-peptide positive (C-pos) patients during hypoglycemia (2.5 mmol/L)
Number of subjects: 21

Group type: COMPARATOR
Intervention: C-peptide negative (C-neg) patients during hypoglycemia (2.5 mmol/L)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups during hypoglycemia
Number of subjects: 21
Study: 29409025

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (Nordic diet recommendations and at least 150 minutes of moderate exercise weekly)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 200
Study: 29409462

Group type: EXPERIMENTAL
Intervention: FREGAT database (prospective database)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatments (endoscopy and surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal treatments (including chemotherapy, targeted therapies, immunotherapy, radiotherapy, and surgery)
Number of subjects: 0
Study: 29409871

Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg or approximately 6 mg/kg intravenous dose for 8 weeks; 90 mg subcutaneous injections every 8 or 12 weeks for 44 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous injections every 8 or 12 weeks for 44 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0